I am Professor of Psychiatry and Neuroscience, Vice Chair for Clinical Research in Psychiatry, and Director of the Depression and Anxiety Center for Discovery and Treatment (DAC) at the Icahn School of Medicine at Mount Sinai (ISMMS). My program of research utilizes molecular, neuroimaging, and experimental therapeutics approaches aimed at elucidating the fundamental mechanisms underlying stress-related disorders in humans, including major depressive disorder (MDD), posttraumatic stress disorder (PTSD) and anxiety disorders. The overall goal of my research is to advance the treatment of stress-related disorders through an enhanced understanding of disease pathogenesis and therapeutic mechanisms of action. Dennis S. Charney is an American biological psychiatrist and researcher, with expertise in the neurobiology and treatment of mood and anxiety disorders. He is the author of Neurobiology of Mental Illness, The Physician's Guide to Depression and Bipolar Disorders and Molecular Biology for the Clinician, as well as the author of over 600 original papers and chapters. In 2022, he was listed #52 on Research.com's "Top Medicine Scientists in the United States," with an h-index of 194 with 146,109 citations across 651 publications. Charney is known for demonstrating that ketamine is effective for treating depression. Ketamine's use as a rapidly-acting anti-depressant is recognized as a breakthrough treatment in mental illness.

• 1. Treatment-Resistant Depression: Epidemiology and Clinical Presentation2. Molecular Neuropharmacology of Treatment-Resistant Depression3. Neurobiology and Neuroimaging of Treatment-Resistant Depression4. Pharmacotherapy of Treatment-Resistant Depression: Overview and Look Ahead5. Lithium, Dopamine Modulators, and Other Augmentation Strategies for Treatment-Resistant Depression6. Ketamine and Esketamine for Treatment-Resistant Depression7. The Impact of Inflammation on Treatment Resistance in Depression: Mechanisms and Translational Opportunities8. Novel Pharmacotherapies for Treatment-Resistant Depression: A Focus on Glutamate and GABA Modulators9. Electroconvulsive Therapy for Treatment-Resistant Depression10. Transcranial Magnetic Stimulation for Treatment-Resistant Depression11. Vagal Nerve Stimulation for Treatment-Resistant Depression12. Deep Brain Stimulation for Treatment-Resistant Depression13. Psilocybin and Other Psychedelic Agents in Development for Treatment-Resistant Depression14. Neuroimaging Biomarkers in Treatment Selection for Treatment-Resistant Depression15. The Role of Genetics in Treatment-Resistant Depression

I am Professor of Psychiatry and Neuroscience, Vice Chair for Clinical Research in Psychiatry, and Director of the Depression and Anxiety Center for Discovery and Treatment (DAC) at the Icahn School of Medicine at Mount Sinai (ISMMS). My program of research utilizes molecular, neuroimaging, and experimental therapeutics approaches aimed at elucidating the fundamental mechanisms underlying stress-related disorders in humans, including major depressive disorder (MDD), posttraumatic stress disorder (PTSD) and anxiety disorders. The overall goal of my research is to advance the treatment of stress-related disorders through an enhanced understanding of disease pathogenesis and therapeutic mechanisms of action. Dennis S. Charney is an American biological psychiatrist and researcher, with expertise in the neurobiology and treatment of mood and anxiety disorders. He is the author of Neurobiology of Mental Illness, The Physician's Guide to Depression and Bipolar Disorders and Molecular Biology for the Clinician, as well as the author of over 600 original papers and chapters. In 2022, he was listed #52 on Research.com's "Top Medicine Scientists in the United States," with an h-index of 194 with 146,109 citations across 651 publications. Charney is known for demonstrating that ketamine is effective for treating depression. Ketamine's use as a rapidly-acting anti-depressant is recognized as a breakthrough treatment in mental illness.

• 1. Treatment-Resistant Depression: Epidemiology and Clinical Presentation2. Molecular Neuropharmacology of Treatment-Resistant Depression3. Neurobiology and Neuroimaging of Treatment-Resistant Depression4. Pharmacotherapy of Treatment-Resistant Depression: Overview and Look Ahead5. Lithium, Dopamine Modulators, and Other Augmentation Strategies for Treatment-Resistant Depression6. Ketamine and Esketamine for Treatment-Resistant Depression7. The Impact of Inflammation on Treatment Resistance in Depression: Mechanisms and Translational Opportunities8. Novel Pharmacotherapies for Treatment-Resistant Depression: A Focus on Glutamate and GABA Modulators9. Electroconvulsive Therapy for Treatment-Resistant Depression10. Transcranial Magnetic Stimulation for Treatment-Resistant Depression11. Vagal Nerve Stimulation for Treatment-Resistant Depression12. Deep Brain Stimulation for Treatment-Resistant Depression13. Psilocybin and Other Psychedelic Agents in Development for Treatment-Resistant Depression14. Neuroimaging Biomarkers in Treatment Selection for Treatment-Resistant Depression15. The Role of Genetics in Treatment-Resistant Depression